<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03167307</url>
  </required_header>
  <id_info>
    <org_study_id>SNF 33IC30_166826</org_study_id>
    <secondary_id>2016-02116</secondary_id>
    <nct_id>NCT03167307</nct_id>
  </id_info>
  <brief_title>The Omega-3 Fatty Acid Paediatric Depression Trial</brief_title>
  <acronym>Omega-3-pMDD</acronym>
  <official_title>OMEGA-3 FATTY ACIDS AS FIRST-LINE TREATMENT IN PAEDIATRIC DEPRESSION. A Phase III, 36-week, Multi-centre, Double-blind, Placebo-controlled Randomized Superiority Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gregor Berger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Psychiatric University Hospital, Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the therapeutic efficacy and safety of omega-3 fatty acids rich in
      eicosapentaenoic acid / docosahexaenoic acid in pediatric depression in a nine months
      double-blind multi-centre study in 220 children and adolescents between 8 and 17 years of
      age. Inflammatory and bioactive lipid markers as predictors of response are evaluated. The
      relationship between omega-3 fatty acids with psychopathology, illness course and cognitive
      parameters will be further investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: About 10% teenagers report moderate to marked depressive symptoms and between
      1-6% will develop a paediatric major depressive disorder (pMDD) until adulthood. However,
      evidence-based treatment approaches are sparse and the use of selective serotonin reuptake
      inhibitors (SSRIs) is heavily debated due to reports of an increase in suicidal ideation and
      limited efficacy in this age group. Growing evidence suggests that omega-3 fatty acids may be
      a beneficial treatment in adult MDD (aMDD) with no published study in teenagers, despite of
      its face validity as a valuable first-line treatment. Meta-analyses of published randomized
      controlled trials (RCTs) in aMDD show moderate effect sizes, if the proportion of
      eicosapentaenoic acid (EPA) is &gt;60% of the total omega-3 fatty acids. One small RCT in
      prepubertal children shows an even larger effect size in favour of omega-3 fatty acids.
      Higher inflammatory mediators (e.g. c-reactive protein, interleukins and others) have been
      reported in aMDD and pMDD. Preliminary data suggests that a proinflammatory state may serve
      as predictor for omega-3 fatty acids response. Furthermore, low levels of omega-3 fatty acids
      have been found in aMDD and pMDD potentially also serving as EPA-response predictors. As MDD
      is a heterogeneous disease entity, such response predictors should be incorporated into MDD
      RCTs.

      Objective: 1) To investigate the therapeutic efficacy and safety of omega-3 fatty acids rich
      in EPA in pMDD, 2) to demonstrate clinical meaningful effects of omega-3 fatty acid
      treatment, 3) to investigate inflammatory and bioactive lipid markers as response predictors,
      and 4) to investigate the relationship between psychopathology (in particular suicidal
      ideation), illness course and cognition in relation to inflammatory and bioactive lipid
      markers. 5.) To establish a tissue repository of phenotypically well characterised children
      and adolescents with pMDD.

      Outcome: The German S3 Guidelines for the treatment of depression in children and youth
      define the background treatment for all participants. All clinical partners will be trained
      and monitored accordingly. The primary outcomes are the (continuous) Children's Depression
      Rating Scale-revised (CDRS-R) total score and the (dichotomous) rates of recovery defined by
      the absence of pMDD for &gt;4months at 36 weeks, as well as response and remission rates at 12
      and 36 weeks. Inflammatory mediators in serum using immunoassays, red blood cell omega-3, 6,
      9 and trans fatty acids using gas chromatography (GC) and bioactive lipid mediators (e.g.
      E-series resolvin) using mass spectrometry (LC-MS/MS) will be measured as potential response
      predictors. Adverse events/ harm endpoints (in particular suicidality) will be coded using
      MedDRA. Adherence measurements are pill counts, as well as n-3 EPA/DHA levels across the
      study. Blood samples will be taken at study entry, week 12 and 36.

      Study design:A Swiss, multicentre, randomised, double-blind, placebo-controlled clinical
      trial.

      Inclusion / Exclusion criteria:The study aims to recruit a sample of 220 individuals aged 8
      -17 years, who are in- or outpatients of a participating centre and have a present primary
      diagnosis of major depressive disorders with depressive symptom of at least moderate
      severity. Participants with pre-existing neurological or medical conditions likely to be
      responsible for the depressive symptoms or other psychopathological diagnoses are excluded.

      Measurement and procedures: The study design incorporates a 1-2week screening, a 1-week
      lead-in and a 36-week double-blind placebo-controlled treatment phase. The severity of the
      depression and psychosocial functioning will be assessed at baseline and at each study visit
      (twice in the acute phase and twice in the maintenance phase) using a variety of different
      questionnaires and rating scales. Cognitive testing and biological markers (blood, urine and
      saliva) will be sampled at baseline and at 12 and 36 weeks. Adherence to the study will be
      checked by pill count at each study visit and polyunsaturated fatty acid (PUFA) level
      measurements in red blood cell membranes at baseline, 12 and 36 weeks will be performed.

      Study product / Intervention: In the proposed study a daily dose of 500mg EPA/ 250mg DHA in
      the 8 to &lt;13 year olds and 1000mg EPA / 500mg DHA in the 13 to &lt;18 years olds (which
      corresponds with the omega-3 fatty acid doses used in adult MDD RCTs) is used as an active
      treatment, respectively. The drug will be administered for 36 weeks. Placebo capsules will
      contain mostly medium chain triglycerides (MCT) and also a small amount of fish oil to mimic
      the fishy flavour and taste. All study medication (active and placebo) will use fish derived
      gelatine capsules and natural orange flavor.

      Sample size justification: This clinical trial aims to include 220 participants in total,
      resulting in 110 participants per treatment group. A sample size calculation was performed
      based on the effect size of 0.54 found in a previous meta-analysis on the effect of omega-3
      fatty acids in aMDD. Sample size calculations were then adjusted for an expected higher
      placebo-response rate in minors and given the multi-centre design. The analysis resulted that
      the inclusion of 108 patients per treatment group will achieve 80% or greater power to detect
      a difference of 20% in response rates between the two treatment groups. The sample of 220
      participants exceeds therefore the projected sample size needed to detect a clinical
      meaningful difference. Participants with no psychopathological follow up data at all will be
      replaced.

      Study duration: The study duration is projected to be about two years and nine months (April
      2017 - January 2020) for patient recruitment and assessment and another year to finish up all
      the analysis and generate the final study report.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A 36-week, multi-centre, double-blind, placebo-controlled randomized superiority Study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>placebo-controlled study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic improvement</measure>
    <time_frame>9 months</time_frame>
    <description>Change of the (continuous) Children's Depression Rating Scale-revised (CDRS-R) total score analyzed using using a linear random coefficient regression model</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recovery rate</measure>
    <time_frame>9 months</time_frame>
    <description>(dichotomous) rates of recovery defined by the absence of pMDD for &gt;4months at 36 weeks according to the Kiddie-Schedule (K-SADS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Remission rate</measure>
    <time_frame>3 months</time_frame>
    <description>remission is defined as a CDRS total score &lt;28</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Remission rate</measure>
    <time_frame>9 months</time_frame>
    <description>remission is defined as a CDRS total score &lt;28</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Response is defined as a 30% decrease in total baseline CDRS sum score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antidepressant medication</measure>
    <time_frame>9 months</time_frame>
    <description>Differences in antidepressant medication between the treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's global assessment scale (CGAS)</measure>
    <time_frame>9 months</time_frame>
    <description>Differences in the scores of the CGAS between treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidscreen quality of life measure for children and adolescents</measure>
    <time_frame>9 months</time_frame>
    <description>Differences in the scores of the Kidscreen between treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>9 months</time_frame>
    <description>Differences in hospital admissions between the treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retention rate</measure>
    <time_frame>9 months</time_frame>
    <description>Differences in retention rate between the treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory mediators as predictors of response</measure>
    <time_frame>Baseline values as predictors for response across the trial</time_frame>
    <description>Omega-3 fatty acid response wil be predicted by the ratio between pro- and anti-inflammatory markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Omega-3 index as predictors of response</measure>
    <time_frame>Baseline values as predictors for response across the trial</time_frame>
    <description>Omega-3 fatty acid response will be predicted by the omega-3 index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolites of EPA as predictors for response</measure>
    <time_frame>Baseline values as predictors for response across the trial</time_frame>
    <description>Omega-3 fatty acid response will be predicted by the levels of direct metabolites of EPA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive Symptoms</measure>
    <time_frame>9 months</time_frame>
    <description>Correlation between severity of depressive symptoms and pro-inflammatory state and omega-3 index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suicidal ideation Questionnaire (SIQ)</measure>
    <time_frame>9 months</time_frame>
    <description>Inverse correlation between omega-3 fatty acids and scores in the SIQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scale of Impulsivity and Emotion Dysregulation (IES-27)</measure>
    <time_frame>9 months</time_frame>
    <description>Correlation between omega-3 index and the overall score of the Scale of Impulsivity and Emotion Dysregulation (IES-27)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between stress, omega-3 fatty acids and saliva cortisol</measure>
    <time_frame>9 months</time_frame>
    <description>Correlation between omega-3 fatty acid levels, scores in the perceived stress scale and saliva cortisol</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Verbal learning and memory test (VLMT)</measure>
    <time_frame>9 months</time_frame>
    <description>Differences in the overall score between the treatment groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Behavior Rating Inventory of Executive Function (BRIEF)</measure>
    <time_frame>9 months</time_frame>
    <description>Differences in the scores of the BRIEF between the treatment groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Tolerability assessed by the Self-reported Antidepressant Side-Effect Checklist (ASEC)</measure>
    <time_frame>9 months</time_frame>
    <description>ASEC total score shows no significant differences between active and placebo</description>
  </other_outcome>
  <other_outcome>
    <measure>Digit span measured by the Wechsler Intelligence Scale for Children (WISC-IV)</measure>
    <time_frame>9 months</time_frame>
    <description>Differences in the overall score of the digit span between the treatment groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Emotion recognition measured with the Amsterdam Neuropsychological Task (ANT) Program</measure>
    <time_frame>9 months</time_frame>
    <description>Significant better scores in emotion recognition of the active compared to the placebo group</description>
  </other_outcome>
  <other_outcome>
    <measure>Attentional flexibility measured with the shifting attentional set of the Amsterdam Neuropsychological Task (ANT) program</measure>
    <time_frame>9 months</time_frame>
    <description>Differences in the reaction times between the treatment groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Regensburg Word Fluency Test (RWT)</measure>
    <time_frame>9 months</time_frame>
    <description>Differences in the number of generated words in the RWT between treatment groups</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Omega-3 fatty acid oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A daily dose of 500mg EPA/ 250mg DHA in the 8 to &lt;13 year olds, and 1000mg EPA / 500mg DHA in the 13 to &lt;18 years olds, respectively, will be added to standardized treatment according to the German S3 Guidelines for the treatment of depression in children and adolescents</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo oil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules will contain mostly medium chain triglycerides (MCT) and also a small amount of fish oil to mimic the fishy flavour and taste. Placebo will be added to standardized treatment according to the German S3 Guidelines for the treatment of depression in children and adolescents</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega 3 fatty acid</intervention_name>
    <description>Omega-3 fatty acids in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines</description>
    <arm_group_label>Omega-3 fatty acid oil</arm_group_label>
    <other_name>Eicosapentaenoic acid (EPA) / docosahexaenoic acid (DHA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oil</intervention_name>
    <description>medium chain triglycerides in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines</description>
    <arm_group_label>Placebo oil</arm_group_label>
    <other_name>medium chain triglycerides</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female in- or outpatients of a participating centre

          -  Children aged 8 &lt;13 years or teenager aged 13 to &lt; 18 years

          -  Major depressive disorder with depressive symptoms of at least moderate severity

          -  Written informed consent of the parents / legal representatives and patients' assent

        Exclusion Criteria:

          -  contraindications to the drug

          -  more than 4 weeks of regular omega-3 supplementation

          -  pregnant or breastfeeding or intention to become pregnant

          -  pre-existing neurological or medical conditions likely to be responsible for
             depressive symptoms

          -  laboratory screening values considered clinically relevant

          -  known or suspected non-compliance

          -  other psychiatric diagnoses (substance dependency, schizophrenia, bipolar affective
             disorder, eating disorder, mental retardation, pervasive developmental disorder)

          -  inability to follow the procedures of the study

          -  Participation in another study with omega-3, previous enrolment in the current study,
             or dependent persons of the investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne Walitza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psychiatrische Universit채tsklinik Z체rich, Klinik f체r Kinder und Jugendpsychiatrie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klaus Schmeck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universit채re Psychiatrische Kliniken (UPK) Basel, Kinder- und Jugendpsychiatrische Klinik</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gregor E Berger, MD</last_name>
    <phone>+41434992626</phone>
    <phone_ext>2671</phone_ext>
    <email>gregor.berger@puk.zh.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle Haeberling, PhD</last_name>
    <phone>+41434992626</phone>
    <email>Isabelle.haeberling@kjpd.uzh.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Psychiatric University Clinics, Department of Child and Adolescent Psychiatry</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregor E Berger, MD</last_name>
      <phone>+41764646154</phone>
      <email>gregor.berger@puk.zh.ch</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle Haeberling, PhD</last_name>
      <phone>+41434992626</phone>
      <email>isabelle.haeberling@uzh.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>https://www.omega3.uzh.ch</url>
    <description>Study website (online from Mai 2017)</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2017</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Psychiatric University Hospital, Zurich</investigator_affiliation>
    <investigator_full_name>Gregor Berger</investigator_full_name>
    <investigator_title>Head of Developmental Psychopharmacology Group, Department of Child and Adolescent Psychiatry</investigator_title>
  </responsible_party>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>eicosapentaenoic acid</keyword>
  <keyword>docosahexaenoic acid</keyword>
  <keyword>antidepressants</keyword>
  <keyword>suicidality</keyword>
  <keyword>cognition</keyword>
  <keyword>childhood depression</keyword>
  <keyword>pediatric depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A BioBank will be established. Access to the Biobank can be requested upon completion of the trial contacting the sponsor-investigator Dr. Gregor Berger</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

